Kancera receives patent grant in US for the drug candidate KAND145
2022-05-25
Kancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera’s fractalkine blocker KAND145. This patent, US 11,339,183, is owned by Kancera and is valid through 2039.
Kancera is developing a new class of drugs that precisely neutralize cancer cells and proinflammatory cells by blocking the fractalkine system. KAND145 belongs to Kancera’s second generation of fractalkine blockers and is in preparatory studies for further development in clinical studies as an orphan drug for cancer and inflammatory diseases.
KAND145 has been designed and developed by Kancera. The approval of the patent application in the US confirms that KAND145 is unique as a chemical structure, meeting the requirements of inventive step and has an industrial application.
“The fact that USA is the first country to issue the patent that protects KAND145 is of great importance because it gives us protection for KAND145 against competition in the most important market for new drugs,” says Thomas Olin, CEO of Kancera AB.
About Kancera AB (publ)
Kancera AB is developing a new class of drugs against inflammation and cancer. The company’s drug candidates operate through a newly discovered control system for immune cells and cancer cells, the so-called fractalkine system. Kancera is studying its most advanced drug candidate KAND567 in two fully funded phase IIa clinical trials of heart, kidney and lung injuries caused by hyperinflammation. Top-line data from the phase IIa study in COVID patients were reported in November 2021. Recruitment of patients for the second phase IIa study, treating inflammation after myocardial infarction, is expected to be completed in 2022. Kancera also conducts preclinical development of the drug candidate KAND145, which primarily is intended for the treatment of autoimmune diseases and cancer. Kancera also develops preclinical drug candidates against hematologic, colorectal and ovarian cancers. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB (info@fnca.se, tel. 08-528 00 399) is the company’s Certified Adviser.
For further information:
Thomas Olin
Chief Executive Officer, Kancera AB
Tel: +46-735-20 40 01
Welcome to visit Kancera’s web page: https://www.kancera.com/en